Evidence map›Paper›PMID 34589570›Full record

ArticleRegenerative engineering and translational medicine2020

Short interfering RNA (siRNA)-Based Therapeutics for Cartilage Diseases.

Libo Zhou, Lee E Rubin, Chuanju Liu, Yupeng Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative engineering and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. A small lipidated peptide targeting NaOsteoarthritis and cartilage open · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Libo ZhouDepartment of Biomedical Engineering, University of Connecticut.
Lee E RubinDepartment of Orthopaedics & Rehabilitation, Yale University School of Medicine.
Chuanju LiuDepartment of Orthopaedic Surgery and Cell Biology, New York University School of Medicine.
Yupeng ChenDepartment of Biomedical Engineering, University of Connecticut.
University of Connecticut · USNew York University · USYale University · US

Funding

Supplement: Developing Nanomaterial Platform for Intra-Cartilage Delivery of RNA Therapeutics against Joint DiseasesR01AR072027 · NIAMS · UNIVERSITY OF CONNECTICUT STORRS · PI CHEN, YUPENG · 2017 to 2022
$2.3M
Growth Plate Cartilage Repair via Novel Matrilin3/Rosette Nanotube Hybrid MatrixR03AR069383 · NIAMS · UNIVERSITY OF CONNECTICUT STORRS · PI CHEN, YUPENG · 2016 to 2018
$242k
NIAMS NIH HHS R01 AR072027NIAMS NIH HHS R03 AR069383
6 · The paper itself

Abstract

Articular cartilage injury, as a hallmark of arthritic diseases, is difficult to repair and causes joint pain, stiffness, and loss of mobility. Over the years, the most significant problems for the drug-based treatment of arthritis have been related to drug administration and delivery. In recent years, much research has been devoted to developing new strategies for repairing or regenerating the damaged osteoarticular tissue. The RNA interference (RNAi) has been suggested to have the potential for implementation in targeted therapy in which the faulty gene can be edited by delivering its complementary Short Interfering RNA (siRNA) at the post-transcriptional stage. The successful editing of a specific gene by the delivered siRNA might slow or halt osteoarthritic diseases without side effects caused by chemical inhibitors. However, cartilage siRNA delivery remains a challenging objective because cartilage is an avascular and very dense tissue with very low permeability. Furthermore, RNA is prone to degradation by serum nucleases (such as RNase H and RNase A) due to an extra hydroxyl group in its phosphodiester backbone. Therefore, successful delivery is the first and most crucial requirement for efficient RNAi therapy. Nanomaterials have emerged as highly advantage tools for these studies, as they can be engineered to protect siRNA from degrading, address barriers in siRNA delivery to joints, and target specific cells. This review will discuss recent breakthroughs of different siRNA delivery technologies for cartilage diseases.

Indexed as

Articular cartilage injuryDelivery therapeuticsNanomaterialsShort interfering RNA

Identifiers

PMID34589570
PMCPMC8478253
OpenAlexW3003229087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.